{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"7230","value":"16900"},{"groupId":"OG001","spread":"9250","value":"21300"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"Area under the plasma concentration-time curve over the dosing interval at steady sate (AUC0-τ,ss) (τ=24 h) following 15 days of QD dosing","dispersionType":"Standard Deviation","groups":[{"description":"Part 1 and Part 2: Patients received a starting dose of 300 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG000","title":"Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD"},{"description":"Part 1 and Part 2: Patients received a starting dose of 400 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG001","title":"Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD"}],"paramType":"MEAN","populationDescription":"Patients enrolled in Part 1 and Part 2 with a starting dose of 300 or 400 mg QD and available samples for PK","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 15","title":"Area Under the Plasma Concentration-time Curve Over the Dosing Interval at Steady Sate (AUC0-τ,ss) (τ=24 h)","type":"SECONDARY","unitOfMeasure":"h*ng/mL"}